Table Info

Table 1.

Demographics and baseline characteristics

Patient characteristics	n (%)	Mean (SD)	Range
Sex
Male	986 (83%)	N/A	N/A
Female	200 (17%)	N/A	N/A
Age in years	N/A	63.3 (14.1)	17–99
Symptom duration at presentation in years	N/A	2.1 (4.8)	1–36
BMI (kg/m²)	N/A	28.13 (5.01)	15.62–59.77
Tophi presence	204 (17.2%)	N/A	N/A
Crystal proof via polarized microscope	875 (82.2%)	N/A	N/A
Disease history
Gout in family	78 (6.5%)	N/A	N/A
Cardiovascular disease	908 (76.5%)	N/A	N/A
Dyslipidemia	499 (42.1%)	N/A	N/A
Type 2 diabetes	254 (21.4%)	N/A	N/A
Renal disease	442 (37.2%)	N/A	N/A
Baseline serum urate (mmol/L)	N/A	0.47 (0.12)	0.13–0.99

n: number; N/A: not applicable

Supplementary materials

The supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/100714_sup_1.pdf.

Declarations

Author contributions

IH: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Visualization, Writing—original draft. TLJ: Conceptualization, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing—review & editing. TG, ME and AC: Resources, Validation. FVO: Formal Analysis. MJ: Methodology, Resources, Validation, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The study was approved by the institutional review board of VieCuri Medical Center (2021-009). The research of this article meets the requirements of the Declaration of Helsinki.

Consent to participate

The VieCuri organization waived for anonymous use of retrospective data from the gout patient population.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

IH was supported by a grad founded by EULAR-Eular scientific training grant for young fellows. The funders had no role in study design, data collection and analysis, the decision to publish, or the preparation of the manuscript.

Copyright

References

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 Updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29–42. [DOI] [PubMed]

Qaseem A, Harris RP, Forciea MA; Clinical Guidelines Committee of the American College of Physicians; Denberg TD, Barry MJ, Boyd C, Chow RD, Humphrey LL, Kansagara D, et al. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166:58–68. [DOI] [PubMed]

Richette P, Clerson P, Périssin L, Flipo RM, Bardin T. Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis. 2015;74:142–7. [DOI] [PubMed]

Riegersperger M, Covic A, Goldsmith D. Allopurinol, uric acid, and oxidative stress in cardiorenal disease. Int Urol Nephrol. 2011;43:441–9. [DOI] [PubMed]

Uhlig T, Karoliussen LF, Sexton J, Borgen T, Haavardsholm EA, Kvien TK, et al. 12-Month results from the real-life observational treat-to-target and tight-control therapy NOR-gout study: achievements of the urate target levels and predictors of obtaining this target. RMD Open. 2021;7:e001628. [DOI] [PubMed] [PMC]

Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018;392:1403–12. [DOI] [PubMed] [PMC]

Te Kampe R, van Durme C, Janssen M, van Eijk-Hustings Y, Boonen A, Jansen TL. Comparative study of real-life management strategies in gout: data from two protocolized gout clinics. Arthritis Care Res (Hoboken). 2020;72:1169–76. [DOI] [PubMed]

Vaccher S, Kannangara DR, Baysari MT, Reath J, Zwar N, Williams KM, et al. Barriers to care in gout: from prescriber to patient. J Rheumatol. 2016;43:144–9. [DOI] [PubMed]

Neogi T, Chen C, Chaisson CE, Hunter DJ, Choi H, Zhang Y. Management of gout attacks in the community. 2012 ACR/ARHP Annual Meeting. Metabolic and crystal arthropathies; 2012 Nov 9–14; Washington, DC. Arthritis Rheum. 2012;64:S66.

10.

Singh JA, Yang S, Saag KG. Factors influencing the effectiveness of allopurinol in achieving and sustaining target serum urate in a US Veterans Affairs gout cohort. J Rheumatol. 2020;47:449–60. [DOI] [PubMed] [PMC]

11.

Stamp LK, Chapman PT, Palmer SC. Allopurinol and kidney function: an update. Joint Bone Spine. 2016;83:19–24. [DOI] [PubMed]

12.

Kim HA, Seo YI, Song YW. Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men. J Korean Med Sci. 2014;29:1077–81. [DOI] [PubMed] [PMC]

13.

Krishnamurthy A, Lazaro D, Stefanov DG, Blumenthal D, Gerber D, Patel S. The effect of allopurinol on renal function. J Clin Rheumatol. 2017;23:1–5. [DOI] [PubMed]

14.

Perez-Ruiz F, Calabozo M, Herrero-Beites AM, García-Erauskin G, Pijoan JI. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron. 2000;86:287–91. [DOI] [PubMed]

15.

Stamp LK, O’Donnell JL, Zhang M, James J, Frampton C, Barclay ML, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63:412–21. [DOI] [PubMed]

16.

Ng KP, Stringer SJ, Jesky MD, Yadav P, Athwal R, Dutton M, et al. Allopurinol is an independent determinant of improved arterial stiffness in chronic kidney disease: a cross-sectional study. PLoS One. 2014;9:e91961. [DOI] [PubMed] [PMC]

17.

Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013;61:134–46. [DOI] [PubMed] [PMC]

18.

Novella-Navarro M, Cabrera-Alarcon JL, Diaz-Torne C, Aramburu-Muñoz F, Janta I, Ortega de la O MC, et al. A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3. Rheumatol Int. 2020;40:1081–7. [DOI] [PubMed]